A Comparison of the Immunogenicity and Descriptive Safety of a Live Attenuated Herpes Zoster Vaccine and the Glaxo Smith Kline (GSK) Herpes Zoster Recombinant HZ/su Candidate Vaccine in 50-59 Year Old and 70-85 Year Old Vaccine Recipients
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Sep 2018
Price : $35 *
At a glance
- Drugs GSK 1437173A (Primary) ; Varicella zoster virus vaccine live
- Indications Herpes zoster; Varicella zoster virus infections
- Focus Pharmacodynamics
- 22 Sep 2018 Results published in the Journal of Infectious Diseases
- 11 Mar 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
- 11 Mar 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Mar 2016, according to ClinicalTrials.gov record.